Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: RNA interference-based therapeutics - Phio Pharmaceuticals

Drug Profile

Research programme: RNA interference-based therapeutics - Phio Pharmaceuticals

Alternative Names: Anti-CTFG RNAi therapy; Anti-VEGF sd-rxRNA; rxRNA®; sd-rxRNA®; Self-delivering RNAi compounds - Phio Pharmaceuticals

Latest Information Update: 05 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator RXi Pharmaceuticals Corporation
  • Developer Phio Pharmaceuticals; RXi Pharmaceuticals; RXi Pharmaceuticals Corporation; University of Massachusetts Medical School
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Antivirals; Eye disorder therapies; Immunotherapies; Obesity therapies; Skin disorder therapies; Small interfering RNA
  • Mechanism of Action Programmed cell death-1 ligand-1 inhibitors; Programmed cell death-1 receptor antagonists; RNA interference; TIGIT protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Eye disorders; Skin disorders

Highest Development Phases

  • Preclinical Cancer; Head and neck cancer; Malignant melanoma; Ovarian cancer
  • No development reported CNS disorders; Eye disorders; Inflammation; Metabolic disorders; Obesity; Respiratory tract disorders; Retinal disorders; Rheumatoid arthritis; Skin disorders
  • Discontinued Cytomegalovirus retinitis

Most Recent Events

  • 21 Nov 2019 Phio Pharmaceuticals and Karolinska Institute enters into a research collaboration to develop RNAi immunotherapies for treating Solid tumors
  • 12 Aug 2019 Preclinical development for Cancer is still ongoing in USA
  • 12 Aug 2019 Phio Pharmaceuticals plans clinical trials for PH 762 as adoptive cell transfer of T cells and direct administration within the tumour micro-environment for Cancer in 2020
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top